Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed250%
terminated125%
not_yet_recruiting125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_3

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

NCT06716021
completedphase_2

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

NCT04467905
terminatedphase_3

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
completedphase_2

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190

Clinical Trials (4)

Showing 4 of 4 trials
NCT06716021Phase 3

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

Not Yet Recruiting
NCT04467905Phase 2

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Completed
NCT03464019Phase 3

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Terminated
NCT02296190Phase 2

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4